Search Results - "Richly, H."

Roles of the Polycomb group proteins in stem cells and cancer by Richly, H, Aloia, L, Di Croce, L

“…Polycomb group proteins have long been linked to the occurrence of different forms of cancer. Polycomb proteins form at least two distinct complexes, the…”
Get full text

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study by Strumberg, D, Scheulen, M E, Schultheis, B, Richly, H, Frost, A, Büchert, M, Christensen, O, Jeffers, M, Heinig, R, Boix, O, Mross, K

“…Background: In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded…”
Get full text

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV by Bergmann, L, Maute, L, Heil, G, Rüssel, J, Weidmann, E, Köberle, D, Fuxius, S, Weigang-Köhler, K, Aulitzky, W E, Wörmann, B, Hartung, G, Moritz, B, Edler, L, Burkholder, I, Scheulen, M E, Richly, H

“…Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumours and is still associated with a poor prognosis in advanced disease. To…”
Get full text

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer by Bergmann, L, Maute, L, Heil, G, Rüssel, J, Weidmann, E, Köberle, D, Fuxius, S, Weigang-Köhler, K, Aulitzky, W.E, Wörmann, B, Hartung, G, Moritz, B, Edler, L, Burkholder, I, Scheulen, M.E, Richly, H

“…Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumours and is still associated with a poor prognosis in…”
Get full text

ZRF1 controls oncogene-induced senescence through the INK4-ARF locus by Ribeiro, J D, Morey, L, Mas, A, Gutierrez, A, Luis, N M, Mejetta, S, Richly, H, Benitah, S A, Keyes, W M, Di Croce, L

“…The reactivation of the INK4-ARF locus, which is epigenetically repressed by Polycomb proteins in healthy cells, is a hallmark of senescence. One mechanism of…”
Get full text

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial by Richly, H, Schultheis, B, Adamietz, I.A, Kupsch, P, Grubert, M, Hilger, R.A, Ludwig, M, Brendel, E, Christensen, O, Strumberg, D

“…Abstract Sorafenib, an oral multikinase inhibitor, shows efficacy in renal cell and hepatocellular carcinoma (HCC) and is well tolerated when combined with…”
Get full text

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors by Richly, H., Henning, B. F., Kupsch, P., Passarge, K., Grubert, M., Hilger, R. A., Christensen, O., Brendel, E., Schwartz, B., Ludwig, M., Flashar, C., Voigtmann, R., Scheulen, M. E., Seeber, S., Strumberg, D.

“…Background: Sorafenib (BAY 43-9006), a novel, oral multi-kinase inhibitor, blocks serine/threonine and receptor tyrosine kinases in the tumor and vasculature…”
Get full text

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer by Mayer, Erica L., Scheulen, M. E., Beckman, J., Richly, H., Duarte, A., Cotreau, M. M., Strahs, A. L., Agarwal, S., Steelman, L., Winer, E. P., Dickler, M. N.

“…Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study…”
Get full text

PP 51 Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel) by Scheulen, M.E, Nokay, B, Richly, H, Hoffmann, A-C, Kalkmann, J, Stattaus, J, Bornfeld, N, Schuler, M.H, Hense, J

Get full text

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis by Hilger, R A, Richly, H, Grubert, M, Kredtke, S, Thyssen, D, Eberhardt, W, Hense, J, Schuler, M, Scheulen, M E

Get full text

Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors by Henke, M M, Richly, H, Drescher, A, Grubert, M, Alex, D, Thyssen, D, Jaehde, U, Scheulen, M E, Hilger, R A

Get full text

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors by Strumberg, D, Voliotis, D, Moeller, J G, Hilger, R A, Richly, H, Kredtke, S, Beling, C, Scheulen, M E, Seeber, S

Get more information

Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors by Richly, H, Grubert, M, Scheulen, M E, Hilger, R A

Get full text

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer by Richly, H, Kupsch, P, Passage, K, Grubert, M, Hilger, R A, Voigtmann, R, Schwartz, B, Brendel, E, Christensen, O, Haase, C G, Strumberg, D

Get full text

Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil by Hilger, R A, Richly, H, Grubert, M, Oberhoff, C, Strumberg, D, Scheulen, M E, Seeber, S

Get full text

A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors by Mross, K., Richly, H., Schleucher, N., Korfee, S., Tewes, M., Scheulen, M. E., Seeber, S., Beinert, T., Schweigert, M., Sauer, U., Unger, C., Behringer, D., Brendel, E., Haase, C. G., Voliotis, D., Strumberg, D.

“…Background: The aim of this study was to define the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetics of the camptothecin…”
Get full text

A phase I clinical and pharmacokinetic study of the raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors by RICHLY, H, KUPSCH, P, PASSAGE, K, GRUBERT, M, HILGER, R. A, KREDTKE, S, VOLIOTIS, D, SCHEULEN, M. E, SEEBER, S, STRUMBERG, D

Get full text

496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours by Scheulen, M, Mross, K, Richly, H, Nokay, B, Frost, A, Scharr, D, Lee, K.H, Saunders, O, Hilbert, J, Fietz, O

Get full text

50 A phase I study of the safety, tolerability and pharmacokinetics of pazopanib (P) in combination with gemcitabine (G) for advanced solid tumors by Richly, H, Rubin, S.D, Madi, A, Jeffels, M, Nokay, B, Gibson, D, Weller, S, Scheulen, M.E, Plummer, R

Get full text

46 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - clinical efficacy and immunological results of a phase I study by Weihrauch, M.R, von Bergwelt-Baildon, M.S, Hacker, U, Richly, H, Holtick, U, Tschaika, M, Schmidt, M, Wittig, B, Nokay, B, Scheulen, M.E

Get full text